Tuesday, 28 January 2014

APPROVAL OF NEW MOLECULAR ENTITIES 2013



1NesinaAlogliptin25-Jan-13To improve blood sugar control in adults with type 2 diabetes.
2KynamroMipomersen sodium29-Jan-13To treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). 
3PomalystPomalidomide8-Feb-13To treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.
4KadcylaAdo-trastuzumab emtansine22-Feb-13For patients with HER2-positive, late-stage (metastatic) breast cancer.
5OsphenaOspemifene26-Feb-13To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.
6LymphoseekTechnetium Tc 99m tilmanocept13-Mar-13A radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumor-draining lymph nodes.
7DotaremGadoterate meglumine20-Mar-13For use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
8TecfideraDimethyl fumarate27-Mar-13To treat adults with relapsing forms of multiple sclerosis (MS).
9Invokanacanagliflozin29-Mar-13Used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.
10Breo ElliptaFluticasone furoate and vilanterol inhalation powder10-May-13For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
11XofigoRadium Ra 223 dichloride15-May-13To treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs.
12TafinlarDabrafenib29-May-13To treat patients with melanoma whose tumors express the BRAF V600E gene mutation.
13MekinistTrametinib29-May-13To treat patients whose tumors express the BRAF V600E or V600K gene mutations. 
14GilotrifAfatinib12-Jul-13For patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. 
15TivicayDolutegravir12-Aug-13To treat HIV-1 infection.
16BrintellixVortioxetine30-Sep-13To treat adults with major depressive disorder.
17DuaveeConjugated estrogens/bazedoxifene3-Oct-13To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause.
18AdempasRiociguat8-Oct-13To treat adults with two forms of pulmonary hypertension.
19OpsumitMacitentan18-Oct-13To treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.
20VizamylFlutemetamol F 18 injection25-Oct-13A radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia.
21GazyvaObinutuzumab1-Nov-13For use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).
22AptiomEslicarbazepine acetate8-Nov-13As an add-on medication to treat seizures associated with epilepsy.
23ImbruvicaIbrutinib13-Nov-13To treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.
24LuzuLuliconozole14-Nov-13For the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older.
25OlysioSimeprevir22-Nov-13  To treat chronic hepatitis C virus infection.
26SovaldiSofosbuvir6-Dec-13  To treat chronic hepatitis C virus (HCV) infection.
27Anoro ElliptaUmeclidinium and vilanterol inhalation powder18-Dec-13                 For the once-daily, long-term maintenance treatment of airflow  obstruction in patients with chronic obstructive pulmonary disease (COPD).
NCK Pharma

Drug Patent Expirations for the week of January 26, 2014

Tuesday, 21 January 2014

Intenational Conference on Drug Delivery ICODD 2014 | February 28th to 1st March | PSG College of Pharmacy, Coimbatore

Drug Patent Expirations for the week of January 19, 2014

Drug Patent Expirations for the week of January 19, 2014
TradenameApplicantGeneric NamePatent No.
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.

Tuesday, 14 January 2014

Drug Patent Expirations for the week of January 12, 2014

Drug Patent Expirations for the week of January 12, 2014
 
TradenameApplicantGeneric NamePatent No.
*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.